Telix Pharmaceuticals Limited (TLX)
NASDAQ: TLX · Real-Time Price · USD
9.56
+0.11 (1.16%)
Jun 12, 2026, 4:00 PM EDT - Market closed
Telix Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 141.87 | 440 | 83.95 | 79.16 | 16.02 |
Cash & Short-Term Investments | 141.87 | 440 | 83.95 | 79.16 | 16.02 |
Cash Growth | -67.76% | 424.12% | 6.05% | 394.22% | -73.31% |
Accounts Receivable | 129.2 | 86.93 | 44.13 | 26.78 | 14.12 |
Inventory | 37.08 | 23.62 | 11.79 | 5.77 | 2.51 |
Other Current Assets | 22.13 | 19.57 | 18.52 | 6.17 | 1.91 |
Total Current Assets | 330.28 | 570.12 | 158.39 | 117.89 | 34.56 |
Net Property, Plant & Equipment | 115.61 | 33.65 | 20.77 | 12.82 | 4.6 |
Other Intangible Assets | 592.82 | 257.86 | 74.7 | 40.14 | 40.51 |
Long-Term Investments | 37.09 | 34.75 | 8.35 | - | - |
Other Long-Term Assets | 88.18 | 44.01 | 14.33 | 2.92 | 0.15 |
Total Assets | 1,164 | 940.38 | 276.54 | 173.77 | 79.82 |
Accounts Payable | 150.35 | 86.79 | 55.66 | 33.7 | 13.84 |
Accrued Expenses | 50.11 | 44.23 | 22.53 | 10.12 | 3.46 |
Current Portion of Long-Term Debt | 13.11 | 11.76 | 0.66 | - | 0.01 |
Current Portion of Leases | 5.55 | 1.55 | 0.41 | 0.44 | 0.45 |
Unearned Revenue | 0.4 | 6.97 | 7.49 | 3.36 | 4.47 |
Other Current Liabilities | 12.1 | 53.79 | 25.7 | 10.61 | 5.38 |
Total Current Liabilities | 231.62 | 205.09 | 112.44 | 58.22 | 27.61 |
Long-Term Debt | 391.91 | 341.81 | 5.59 | 2.25 | - |
Long-Term Leases | 56.53 | 5.04 | 5.23 | 4.42 | 1.39 |
Other Long-Term Liabilities | 68.54 | 35.5 | 51.84 | 54.43 | 49.26 |
Total Long-Term Liabilities | 516.99 | 382.35 | 62.66 | 61.1 | 50.64 |
Total Liabilities | 748.61 | 587.44 | 175.1 | 119.32 | 78.25 |
Common Stock | 479.96 | 414.01 | 304 | 252.45 | 124.18 |
Additional Paid-in Capital | -11.61 | 15.95 | -42.8 | -11.97 | 4.32 |
Accumulated Other Comprehensive Income | 101.56 | 75.89 | 19.85 | -0.38 | -0.84 |
Retained Earnings | -154.54 | -152.91 | -179.61 | -185.65 | -126.09 |
Shareholders' Equity | 415.38 | 352.94 | 101.44 | 54.44 | 1.57 |
Total Liabilities & Equity | 1,164 | 940.38 | 276.54 | 173.77 | 79.82 |
Total Debt | 467.11 | 360.16 | 11.88 | 7.11 | 1.85 |
Net Cash (Debt) | -325.24 | 79.84 | 72.07 | 72.05 | 14.17 |
Net Cash Growth | - | 10.78% | 0.02% | 408.42% | -75.70% |
Net Cash Per Share | -0.96 | 0.23 | 0.22 | 0.23 | 0.05 |
Book Value | 415.38 | 352.94 | 101.44 | 54.44 | 1.57 |
Book Value Per Share | 1.23 | 1.02 | 0.31 | 0.18 | 0.01 |
Tangible Book Value | -177.45 | 95.08 | 26.74 | 14.31 | -38.94 |
Tangible Book Value Per Share | -0.53 | 0.28 | 0.08 | 0.05 | -0.14 |